Modulation of cytokine production by carnitine

The ability of carnitine congeners to modulate cytokine production by human peripheral blood mononuclear cells (PBMC) was investigated. Modulation of cytokine production by PBMC of young (30 years of age or younger) and old (70 years of age or older) normal donors was first compared. The PBMC were collected over Ficoll–Hypaque and incubated in the presence of various concentrations of acetyl L-carnitine for 24 h. Subsequently the supernatants were collected and examined for cytokine production. The presence of cytokines in tissue culture supernatants was examined by ELISA. The cytokines measured included IL-1α, IL-1β, IL-2, IL-4, IL-6, TNFα, GM–CSF, and IFNγ. The results showed that at 50 μg/ml of acetyl L-carnitine the most significant response was obtained for TNFα. In this regard four of five young donors responded, but only one of five old donors responded. More recently these studies were expanded to examine the ability of L-carnitine to modulate cytokine production at higher doses, 200 and 400 μg/ml, in young donors. The results of these studies showed that in addition to TNFα, significant production of IL-1β and IL-6 was observed. These preliminary studies provide evidence that carnitine may modulate immune functions through the production of selected cytokines.

[1]  G. Finocchiaro,et al.  Molecular characterization of inherited carnitine palmitoyltransferase II deficiency. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[2]  H. Quinney,et al.  Carnitine stimulation of glucose oxidation in the fatty acid perfused isolated working rat heart. , 1992, The Journal of biological chemistry.

[3]  V. Vullo,et al.  L‐carnitine deficiency in AIDS patients , 1992, AIDS.

[4]  J. Saudubray,et al.  Infantile form of carnitine palmitoyltransferase II deficiency with hepatomuscular symptoms and sudden death. Physiopathological approach to carnitine palmitoyltransferase II deficiencies. , 1991, The Journal of clinical investigation.

[5]  M. Rocchi,et al.  cDNA cloning, sequence analysis, and chromosomal localization of the gene for human carnitine palmitoyltransferase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[6]  C. De Simone,et al.  Effects of acetyl-L-carnitine oral administration on lymphocyte antibacterial activity and TNF-alpha levels in patients with active pulmonary tuberculosis. A randomized double blind versus placebo study. , 1991, Immunopharmacology and immunotoxicology.

[7]  C. Pepine.  The therapeutic potential of carnitine in cardiovascular disorders. , 1991, Clinical therapeutics.

[8]  F. Di Lisa,et al.  Clinical use of carnitine. Past, present and future. , 1990, Advances in experimental medicine and biology.

[9]  M. Mokotoff,et al.  Thymosin-like peptides as potential immunostimulants. Synthesis via the polymeric-reagent method. , 1990, Journal of medicinal chemistry.

[10]  D. Monti,et al.  Immunomodulatory properties of L-acetylcarnitine on lymphocytes from young and old humans , 1989 .

[11]  L. Lu,et al.  Production of human B and T cell growth factors is enhanced by thymic hormones. , 1988, Immunopharmacology.

[12]  K. Sundqvist,et al.  L-carnitine enhances lymphocyte mitogenesis in depleted traumatised and infected patients , 1987 .

[13]  S. Pathak,et al.  Establishment of stable human T-T hybridomas. , 1985, Journal of immunological methods.

[14]  L. Bieber,et al.  Carnitine octanoyltransferase of mouse liver peroxisomes: properties and effect of hypolipidemic drugs. , 1983, Archives of biochemistry and biophysics.

[15]  C. De Simone,et al.  Vitamins and immunity: II. Influence of L-carnitine on the immune system. , 1982, Acta vitaminologica et enzymologica.